1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of european experience and conclusions

T. Philip, R. Ladenstein, C. Lasset, O. Hartmann, J. M. Zucker, R. Pinkerton, A. D J Pearson, T. Klingebiel, A. Garaventa, B. Kremens, J. L. Bernard, G. Rosti, F. Chauvin

Research output: Contribution to journalArticle

Abstract

1070 myeloablative procedures followed by stem cell rescue for neuroblastoma are reviewed. These 1070 procedures are part of the European Group for Blood and Marrow Transplant (EBMTG) registry from the last 17 years (in 4536 patients). In 1070 neuroblastoma patients, survival at 2 years was 49%, at 5 years, 33% and relapses were observed as late as 7 years post-BMT (bone marrow transplant). However, 5=year survivors after megatherapy with BMT for stage 4 disease do have an 80% chance of becoming a long-term survivor. When BMT had been used in first complete response (CR1) no salvage was possible, whereas 15% survivors may be seen if BMT is used for the first time at relapse. Infants with stage 4 neuroblastoma had a 17% toxic death rate and indication in this group is exceptional and not recommended. In a matched cohort (17 allogeneic and 34 autologous), autologous stem cell rescue (SCR) was shown to be at least equal to allogeneic SCR. Multivariate analysis of clinical prognostic factors in children with stage 4 disease over 1 year showed that event=free survival was mainly influenced by two adverse factors before the megatherapy procedure: persisting skeleton lesions (99Tc and/or mIBG scan positive) as well as persisting bone marrow (BM) involvement.

Original languageEnglish
Pages (from-to)2130-2135
Number of pages6
JournalEuropean Journal of Cancer
Volume33
Issue number12
DOIs
Publication statusPublished - Oct 1997

Fingerprint

Neuroblastoma
Survivors
Stem Cells
Bone Marrow
Transplants
Recurrence
Poisons
Blood Group Antigens
Skeleton
Disease-Free Survival
Registries
Multivariate Analysis
Survival
Mortality

Keywords

  • EBMT
  • Myeloablative therapy
  • Neuroblastoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma : 17 years of european experience and conclusions. / Philip, T.; Ladenstein, R.; Lasset, C.; Hartmann, O.; Zucker, J. M.; Pinkerton, R.; Pearson, A. D J; Klingebiel, T.; Garaventa, A.; Kremens, B.; Bernard, J. L.; Rosti, G.; Chauvin, F.

In: European Journal of Cancer, Vol. 33, No. 12, 10.1997, p. 2130-2135.

Research output: Contribution to journalArticle

Philip, T, Ladenstein, R, Lasset, C, Hartmann, O, Zucker, JM, Pinkerton, R, Pearson, ADJ, Klingebiel, T, Garaventa, A, Kremens, B, Bernard, JL, Rosti, G & Chauvin, F 1997, '1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of european experience and conclusions', European Journal of Cancer, vol. 33, no. 12, pp. 2130-2135. https://doi.org/10.1016/S0959-8049(97)00324-9
Philip, T. ; Ladenstein, R. ; Lasset, C. ; Hartmann, O. ; Zucker, J. M. ; Pinkerton, R. ; Pearson, A. D J ; Klingebiel, T. ; Garaventa, A. ; Kremens, B. ; Bernard, J. L. ; Rosti, G. ; Chauvin, F. / 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma : 17 years of european experience and conclusions. In: European Journal of Cancer. 1997 ; Vol. 33, No. 12. pp. 2130-2135.
@article{243446463f664721a26c24e63dc13a25,
title = "1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of european experience and conclusions",
abstract = "1070 myeloablative procedures followed by stem cell rescue for neuroblastoma are reviewed. These 1070 procedures are part of the European Group for Blood and Marrow Transplant (EBMTG) registry from the last 17 years (in 4536 patients). In 1070 neuroblastoma patients, survival at 2 years was 49{\%}, at 5 years, 33{\%} and relapses were observed as late as 7 years post-BMT (bone marrow transplant). However, 5=year survivors after megatherapy with BMT for stage 4 disease do have an 80{\%} chance of becoming a long-term survivor. When BMT had been used in first complete response (CR1) no salvage was possible, whereas 15{\%} survivors may be seen if BMT is used for the first time at relapse. Infants with stage 4 neuroblastoma had a 17{\%} toxic death rate and indication in this group is exceptional and not recommended. In a matched cohort (17 allogeneic and 34 autologous), autologous stem cell rescue (SCR) was shown to be at least equal to allogeneic SCR. Multivariate analysis of clinical prognostic factors in children with stage 4 disease over 1 year showed that event=free survival was mainly influenced by two adverse factors before the megatherapy procedure: persisting skeleton lesions (99Tc and/or mIBG scan positive) as well as persisting bone marrow (BM) involvement.",
keywords = "EBMT, Myeloablative therapy, Neuroblastoma",
author = "T. Philip and R. Ladenstein and C. Lasset and O. Hartmann and Zucker, {J. M.} and R. Pinkerton and Pearson, {A. D J} and T. Klingebiel and A. Garaventa and B. Kremens and Bernard, {J. L.} and G. Rosti and F. Chauvin",
year = "1997",
month = "10",
doi = "10.1016/S0959-8049(97)00324-9",
language = "English",
volume = "33",
pages = "2130--2135",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "12",

}

TY - JOUR

T1 - 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma

T2 - 17 years of european experience and conclusions

AU - Philip, T.

AU - Ladenstein, R.

AU - Lasset, C.

AU - Hartmann, O.

AU - Zucker, J. M.

AU - Pinkerton, R.

AU - Pearson, A. D J

AU - Klingebiel, T.

AU - Garaventa, A.

AU - Kremens, B.

AU - Bernard, J. L.

AU - Rosti, G.

AU - Chauvin, F.

PY - 1997/10

Y1 - 1997/10

N2 - 1070 myeloablative procedures followed by stem cell rescue for neuroblastoma are reviewed. These 1070 procedures are part of the European Group for Blood and Marrow Transplant (EBMTG) registry from the last 17 years (in 4536 patients). In 1070 neuroblastoma patients, survival at 2 years was 49%, at 5 years, 33% and relapses were observed as late as 7 years post-BMT (bone marrow transplant). However, 5=year survivors after megatherapy with BMT for stage 4 disease do have an 80% chance of becoming a long-term survivor. When BMT had been used in first complete response (CR1) no salvage was possible, whereas 15% survivors may be seen if BMT is used for the first time at relapse. Infants with stage 4 neuroblastoma had a 17% toxic death rate and indication in this group is exceptional and not recommended. In a matched cohort (17 allogeneic and 34 autologous), autologous stem cell rescue (SCR) was shown to be at least equal to allogeneic SCR. Multivariate analysis of clinical prognostic factors in children with stage 4 disease over 1 year showed that event=free survival was mainly influenced by two adverse factors before the megatherapy procedure: persisting skeleton lesions (99Tc and/or mIBG scan positive) as well as persisting bone marrow (BM) involvement.

AB - 1070 myeloablative procedures followed by stem cell rescue for neuroblastoma are reviewed. These 1070 procedures are part of the European Group for Blood and Marrow Transplant (EBMTG) registry from the last 17 years (in 4536 patients). In 1070 neuroblastoma patients, survival at 2 years was 49%, at 5 years, 33% and relapses were observed as late as 7 years post-BMT (bone marrow transplant). However, 5=year survivors after megatherapy with BMT for stage 4 disease do have an 80% chance of becoming a long-term survivor. When BMT had been used in first complete response (CR1) no salvage was possible, whereas 15% survivors may be seen if BMT is used for the first time at relapse. Infants with stage 4 neuroblastoma had a 17% toxic death rate and indication in this group is exceptional and not recommended. In a matched cohort (17 allogeneic and 34 autologous), autologous stem cell rescue (SCR) was shown to be at least equal to allogeneic SCR. Multivariate analysis of clinical prognostic factors in children with stage 4 disease over 1 year showed that event=free survival was mainly influenced by two adverse factors before the megatherapy procedure: persisting skeleton lesions (99Tc and/or mIBG scan positive) as well as persisting bone marrow (BM) involvement.

KW - EBMT

KW - Myeloablative therapy

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=0031431549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031431549&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(97)00324-9

DO - 10.1016/S0959-8049(97)00324-9

M3 - Article

C2 - 9516868

AN - SCOPUS:0031431549

VL - 33

SP - 2130

EP - 2135

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 12

ER -